Status:
WITHDRAWN
68-Ga-FAPI PET Imaging in Malignancy
Lead Sponsor:
Stanford University
Conditions:
Cancer
Eligibility:
All Genders
19-99 years
Phase:
PHASE2
Brief Summary
This feasibility trial studies the use of gallium-68 (68Ga)-FAPI as the imaging agent for positron emission tomography (PET)/computed tomography (CT), collectively PET/CT, in patients with various can...
Detailed Description
PRIMARY OBJECTIVE: To assess feasibility and biodistribution of PET imaging in malignancy using 68Ga-FAPI. OUTLINE: Patients receive 68Ga-FAPI intravenously (IV) and then undergo PET/CT approximate...
Eligibility Criteria
Inclusion
- Patient with current malignancy confirmed via pathology or imaging
- Patient must be \> 18 years old
- Patient must be willing and able to provide written informed consent for the trial
- Patient of reproductive potential will have a pregnancy test
Exclusion
- Pregnant or breastfeeding
Key Trial Info
Start Date :
July 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 14 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04023240
Start Date
July 1 2023
End Date
December 14 2023
Last Update
August 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University Hospitals and Clinics
Stanford, California, United States, 94305